

Around the world of U.S. healthcare in 360 words or less


Center for Healthcare Regulatory Insight

March 18, 2022 | Issue 213

Editor's note

This note is produced every Friday by the <u>KPMG Center for Healthcare Regulatory</u> <u>Insight</u> and is intended to be short and succinct, no more than 360 words, to provide a digestible bite of healthcare and life sciences news from the past week. Please share this email with colleagues and other interested individuals, and encourage them to <u>subscribe to our mailing list here</u>.

We welcome your feedback. Let us know if KPMG can help. Please <u>reply here to me</u>, **Larry Kocot**, principal and national leader, KPMG Center for Healthcare Regulatory Insight or simply reply to this email with any comments or requests.



Special Supplement: COVID-19 News

In light of the continuing daily volume of COVID-19 activity and news, we have summarized <u>COVID-19 news for the week in this special supplement</u>.

0



Healthcare regulatory news

OMB is reviewing an <u>FDA proposed rule</u> to support prescription drugs becoming available over-the-counter and <u>CMS proposed rule</u> to fix the ACA's "family glitch."

CMS may <u>adjust Medicare Part B premiums after finalizing its Aduhelm coverage policy</u>... HHS Secretary Xavier Becerra hopes to <u>work with Congress on physician payment and</u> <u>Medicare Advantage</u> (MA) reform.

CMS <u>released states' final FY2018-2019 DSH allotments</u> and preliminary FY2020-2021 allotments.

OIG reported <u>over 28M Medicare beneficiaries used telehealth</u> in the pandemic's first year; use was up 88 times from the previous year.

FDA <u>published FY2022 fee rates</u> for the over-the-counter monograph drug user fee program.

0



Healthcare law and policy news

President Biden signed the \$1.5T omnibus spending bill.

MedPAC <u>recommended</u> FY2023 Medicare <u>provider payment rates</u> to Congress and that CMS require clinicians to <u>use a claims modifier to identify</u> audio-only telehealth visits... MedPAC estimated MA plans <u>received \$12 billion more</u> in payments than they would have for fee-for-service beneficiaries.

A jury found <u>Sutter Health not guilty of federal antitrust</u> allegations... A <u>federal court</u> <u>ruled</u> HHS <u>exceeded its legal authority</u> in a letter demanding AstraZeneca honor 340B discounts at contract pharmacies; Gilead became <u>the 15th drug manufacturer</u> to <u>restrict</u> <u>such discounts</u>... A district court will <u>allow a class action suit to proceed alleging Aetna</u> coverage limits violate ERISA... Blues plans <u>sued Walgreens for allegedly overcharging for</u> <u>prescription drugs</u>.

Clarify Health <u>acquired Embedded Healthcare</u>... Eisai agreed to <u>give Biogen full control</u> over Aduhelm's regulatory/sales decisions; Biogen reported Aduhelm <u>reduced two</u>

<u>Alzheimer's key indicators</u> in patients treated for 2+ years... NIH launched a clinical trial evaluating three <u>mRNA-based HIV vaccines</u>.

VA <u>released recommendations</u> to the Asset and Infrastructure Review (AIR) Commission to modernize/realign the VA health system.

A <u>JAMA study</u> found Black Americans <u>fatally overdosed in 2020 at a higher rate than</u> <u>White Americans for the first time</u> since 1999... <u>Commonwealth Fund reported</u> US adults are less likely than adults in 11 other high-income countries to have a longstanding primary care provider (PCP) relationship or access to PCPs for home and after-hours visits... KFF-Epic reported <u>telehealth accounted for 36%</u> of outpatient mental health/substance abuse disorder visits March-August 2021.

CDC reported <u>12.5% of adults used cigarettes in 2020</u>, the lowest recorded since 1965.





Questions or comments, please send to <u>us-hcinsight@kpmg.com</u>.

kpmg.com/socialmedia



Privacy | Legal

This email was sent by KPMG LLP, 3 Chestnut Ridge Road, Montvale, NJ 07645

© 2022 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. NDP295619-1A

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.



COVID-19 News Supplement

Center for Healthcare Policy Insight



COVID-19 by the Numbers

<u>Over 79.6 million COVID-19 cases</u> have been documented in the US, with a death toll over 970,000... The country <u>averaged roughly 30,000 cases/day</u> over the past week, down approximately 40% over the past two weeks; COVID-related deaths averaged less than 1,200/day over the past week... World Health Organization (WHO) reported <u>global COVID-19 cases rose 8% over the last week</u>, including 29% in the Western Pacific, while deaths fell 17%... Some experts are <u>warning about the risk of another resurgence</u> in <u>COVID-19 cases</u> in the US due to relaxed COVID policies, growing spread of the BA.2 variant, and waning immunity.

More than <u>11 billion COVID-19 vaccine doses have been administered across 184 countries</u>... Over 557 million COVID-19 <u>vaccine doses have been administered</u> in the US... Over 254.7 million Americans (<u>approximately 81.6% of Americans 5 and older</u>) have received at least one COVID-19 vaccine dose; over 216.8 million Americans are fully vaccinated (69.4% of Americans 5 and older); over 96 million Americans have received a booster or additional dose (just 44.4% of those fully vaccinated).

Executive and Administrative Action

White House COVID-19 response coordinator <u>Jeff Zients will step down in April</u> and be replaced by Dr. Ashish K. Jha, Dean of the Brown University School of Public Health.

Congress <u>failed to pass</u> a standalone COVID-19 relief funding bill... The White House <u>detailed the impacts</u> of no additional pandemic relief funds, including canceling orders of monoclonal antibodies and vaccine boosters, reducing testing capacity, scaling back the COVID-19 Uninsured Program, and possibly being unable to purchase more antiviral pills. The Biden Administration plans to work with insurers to manage the "unwinding" of the public health emergency, including ensuring <u>private insurer payment/coverage</u> for COVID-19 vaccines and treatments.

The Administration is seeking to <u>expand (and make permanent) a federal COVID-19 data program</u> to better track the burden of respiratory and other infectious diseases on hospitals... the Administration is urging WHO to <u>encourage manufacturers to voluntarily share products and technologies</u> in the next pandemic in order to improve equity.

A pending proposed rule would have <u>CDC regain its role as the primary agency collecting hospital data</u> on infectious disease threats.

GAO <u>commended TSA's response to the pandemic</u>, including expedited coordination with external stakeholder to develop and issue directives on restricting air travel from certain countries and mandating the use of face masks.

© 2022 KPMG LLP, a Delaware limited liability partnership and the U.S. member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.

The Senate voted 57-40 to end the federal mask mandate on planes and other public transportation.

Healthcare Law, Business, and Policy News

A <u>Lancet study found</u> serious COVID-19 illness is linked to long-term adverse symptoms in individuals' mental health... A <u>JAMA study found</u> using crisis standards of care (CSOC) scores designed to allocate scarce resources during the COVID-19 pandemic resulted in lower prioritization of Black patients to receive those scarce resources, exacerbating racial disparities.

A CDC study found <u>children ages 0 to 4 were five times as likely to be hospitalized because of a COVID-19 infection from the Omicron variant</u> as compared to an infection from the Delta variant... A <u>JAMA</u> <u>Pediatrics study</u> detailed the negative impacts of the pandemic on children's health, including increased levels of anxiety and depression, decreased daily physical activity, decreased preventive medical visits; and increased child care disruption affecting parental employment.

An Axios/Ipsos survey found <u>64% of respondents support federal, state, and local governments</u> lifting all COVID-19 restrictions, up 20 percentage points from early February; however, 74% are likely to wear a mask outside if cases surged in their area.

Hospitals and supply chain experts raised concerns about possible <u>shortages of dextrose and saline</u> <u>solutions</u> necessary for routine care and delivery of medications.

Surveillance, Testing, and Treatment

Pfizer and BioNTech are <u>seeking emergency use authorization for a second COVID-19 booster vaccine</u> for individuals 65 and older... Pfizer's CEO indicated a <u>fourth dose of its COVID-19 vaccine would likely be</u> <u>necessary</u> to maintain manageable levels of hospitalizations and keep infections mild.

Moderna requested FDA grant <u>emergency use authorization for a fourth dose of its COVID-19 vaccine</u> for adults who already received a booster does of any approved or authorized vaccine... earlier in the week, Moderna's President said that a <u>second booster is probably only necessary</u> for older individuals or those who are immunocompromised.

During <u>an event</u>, CDC Director Rochelle Walensky said a second round of COVID-19 booster doses would require additional funding and resources to acquire and administer.

A <u>CDC study</u> concluded Pfizer-BioNTech's COVID-19 vaccine is only "moderately" effective against the Omicron variant in children ages 5 to 11 (infection risk reduction of 31%), as compared to 59% effective in children ages 12 to 15.

Alnylam Pharmaceuticals <u>filed separate lawsuits</u> against Pfizer and Moderna seeking compensation for allegedly infringing a patent in manufacture and sale of their mRNA COVID-19 vaccines.

Recent data suggest <u>Johnson & Johnson's COVID-19 vaccine is as effective as mRNA-based vaccines</u> at preventing infections, hospitalization, and deaths.

The US, European Union, South Africa, and India <u>reached an intellectual property deal</u> that would allow countries with low vaccine exports to <u>use patented vaccine formulas without approval</u> from the manufacturer.

The Medicines Patent Pool announced an <u>agreement with 35 companies around the world</u> to manufacture a generic version of Paxlovid... Meanwhile, *Bloomberg* reported <u>many countries are</u> <u>unlikely to have access or supplies of Paxlovid</u> for at least a year.